
Fenbufen
CAS No. 36330-85-5
Fenbufen ( Fenbufen | Cinopal | Lederfen | CL-82204 | CL 82204 | CL82204 )
产品货号. M14247 CAS No. 36330-85-5
芬布芬是一种丙酸衍生物类非甾体抗炎药。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
50MG | ¥308 | 有现货 |
![]() ![]() |
100MG | ¥413 | 有现货 |
![]() ![]() |
200MG | ¥640 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Fenbufen
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述芬布芬是一种丙酸衍生物类非甾体抗炎药。
-
产品描述Fenbufen is a non-steroidal anti-inflammatory drug in the propionic acid derivatives class.(In Vitro):Fenbufen (100-500 μM) improves the viability of apoptotic THP-1 cells treated with 25 μM Nigericin (HY-127019).(In Vivo):Fenbufenmay (1200 mg/kg; feed) does not cause gastric ulceration whilst inducing a near maximal inhibition of prostaglandin release in rats.Fenbufenmay (1200 mg/kg; p.o.; diet; for 10 days) blocks the hypertrophy of the heart but not that of the skeletal muscles.
-
体外实验Fenbufen (100-500 μM) improves the viability of apoptotic THP-1 cells treated with 25 μM Nigericin (HY-127019).
-
体内实验Fenbufenmay (1200 mg/kg; feed) does not cause gastric ulceration whilst inducing a near maximal inhibition of prostaglandin release in rats.Fenbufenmay (1200 mg/kg; p.o.; diet; for 10 days) blocks the hypertrophy of the heart but not that of the skeletal muscles. Animal Model:Male hooded Lister ratsDosage:1200 mg/kg Administration:Oral administration, diet, for 10 days Result:Significantly reduced Clenbuterol (2mg/kg)-induced hypertrophy of the heart.
-
同义词Fenbufen | Cinopal | Lederfen | CL-82204 | CL 82204 | CL82204
-
通路Endocrinology/Hormones
-
靶点ATPase
-
受体ATP systhesis
-
研究领域Inflammation/Immunology
-
适应症——
化学信息
-
CAS Number36330-85-5
-
分子量254.28
-
分子式C16H14O3
-
纯度>98% (HPLC)
-
溶解度DMSO: 10 mM
-
SMILESO=C(O)CCC(C1=CC=C(C2=CC=CC=C2)C=C1)=O
-
化学全称4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Yang Y, Gao H. Spectrochim Acta A Mol Biomol Spectrosc. 2013 Jan 15;101:119-26.
产品手册




关联产品
-
Trichlormethiazide
三氯甲噻嗪是一种噻嗪类利尿剂,其性质与氢氯噻嗪相似。
-
PK095
PK095 是一种 p53 突变体稳定剂。PK095 可用于癌症研究。
-
3′,4′,7-Trihydroxyfl...
7,3',4'-三羟基黄酮通过活化 T 细胞 c1 的核因子抑制破骨细胞生成。 7,3',4'-TriHydroxyflavone 可显着抑制核因子 kappa B 配体受体激活剂诱导的小鼠骨髓源性巨噬细胞 (BMM) 破骨细胞分化。